Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Moonlake Immunotherapeutics (MLTX)

145 + Investors. Track Smart Money conviction in MLTX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +15
Streak
1Q ▲
Buyers last Q
56%

Smart Money Signals — MLTX

Based on 146 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added MLTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
146 hedge funds hold MLTX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +4% more funds vs a year ago

fund count last 6Q
+6 new funds entered over the past year (+4% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 56% buying

90 buying71 selling
Last quarter: 90 funds bought or added vs 71 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~40 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 22 → 51 → 42 → 40. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 35% long-term, 38% new

■ 35% conviction (2yr+) ■ 27% medium ■ 38% new
Of the 146 current holders: 51 (35%) held >2 years, 39 held 1–2 years, and 56 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +50% but shares only +7% — price-driven

Value
+49%
Shares
+6%
Last quarter: the total dollar value of institutional holdings rose +50%, but actual share count only changed +7%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

37 → 22 → 51 → 42 → 40 new funds/Q
New funds entering each quarter: 22 → 51 → 42 → 40. A growing number of institutions are discovering MLTX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 53% veterans vs 36% newcomers

■ 53% veterans ■ 12% 1-2yr ■ 36% new
Entry-cohort mix of 156 holders: 82 (53%) are 2+ year veterans, 18 entered 1–2 years ago, and 56 (36%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 20% AUM from major funds

20% from top-100 AUM funds
32 of 144 holders rank in the top 100 by AUM, accounting for 20% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.0
out of 10
Moderate Exit Risk
Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MLTX

In 2026 Q1, 90 hedge funds were net buyers of MLTX (40 opened a new position, 50 added to an existing one), while 71 reduced or exited (46 trimmed, 25 sold completely) — a 56% buyer ratio, indicating a slight buying edge. 20% of total institutional value in MLTX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +15 funds (more new holders than closures). Total institutional holders: 146.

Hedge Fund Ownership: MLTX

How many hedge funds hold MLTX — quarterly history vs. share price
Quarterly hedge fund ownership of MLTX vs. share price

Market Analysis: MLTX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MLTX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Moonlake Immunotherapeutics (MLTX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MLTX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 77d ago
MLTX
+3.0%
XLV
nan%

MLTX outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 32d ago
MLTX
+9.3%
XLV
nan%

Since the filing became public, MLTX outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

13 top-rated funds 6 high-conviction
Consensus
5.0
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: MLTX
145 + Investors

Track Smart Money conviction in MLTX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 145 131 10.69%
13F Shares 64M 60M 6.91%
Total Value $1.16B $777M 49.73%
New Positions 39 42 -3
Increased Positions 44 59 -15
Closed Positions 25 56 -31
Reduced Positions 46 25 +21
Total Calls 8 9 -11.11%
Total Puts 4 7 -42.86%
PUT/CALL Ratio 0.5 0.78 Bullish

Statistics: MLTX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

145 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MLTX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MLTX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Bvf Inc/Il 9.50% 16,001,284 $298.3M
2 Lion Point Capital, LP 7.52% 67,500 $1.3M
3 Cormorant Asset Management, LP 4.19% 4,480,433 $83.5M
4 Ishara Investments LP 3.08% 174,250 $3.2M
5 Kalehua Capital Management LLC 2.76% 175,734 $3.3M
6 MPM BioImpact LLC 2.61% 1,811,082 $33.8M
7 Acuta Capital Partners, LLC 2.52% 191,760 $3.6M
8 Great Point Partners LLC 2.14% 500,000 $9.3M
9 Exome Asset Management LLC 2.08% 215,376 $4.0M
10 Deep Track Capital, LP 1.95% 6,408,863 $119.5M
11 Vivo Capital, LLC 1.56% 1,000,000 $18.6M
12 Logos Global Management LP 1.40% 1,500,000 $28.0M
13 HighVista Strategies LLC 1.00% 193,955 $3.6M
14 Boxer Capital Management, LLC 0.67% 275,000 $5.1M
15 First Turn Management, LLC 0.66% 315,563 $5.9M
16 Casdin Capital, LLC 0.64% 450,000 $8.4M
17 Rhenman & Partners Asset Management AB 0.55% 239,500 $4.5M
18 Weiss Asset Management LP 0.54% 1,708,328 $31.8M
19 ADAR1 Capital Management, LLC 0.50% 457,137 $8.5M
20 Longaeva Partners L.P. 0.28% 410,000 $7.6M
21 Crystal Cove Asset Management, LLC 0.22% 10,000 $186K
22 Optimize Financial Inc 0.22% 24,419 $455K
23 Headlands Technologies LLC 0.21% 97,133 $1.8M
24 Granahan Investment Management, LLC 0.20% 220,600 $4.1M
25 Avidity Partners Management LP 0.19% 50,000 $819K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Moonlake Immunotherapeutics (MLTX)

What does the Smart Money Trend signal show for MLTX?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added MLTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MLTX?

Slight buying edge — 56% buying: Last quarter: 90 funds bought or added vs 71 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MLTX holders?

Strong quality — 20% AUM from major funds: 32 of 144 holders rank in the top 100 by AUM, accounting for 20% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held MLTX?

Mixed — 35% long-term, 38% new: Of the 146 current holders: 51 (35%) held >2 years, 39 held 1–2 years, and 56 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Moonlake Immunotherapeutics (MLTX) following the 2026 Q1 hedge fund 13F filings?

As of today, MLTX has moved +9.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to nan% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), MLTX has gained +3.0% vs nan% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →